Loading…

Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy

Gender-affirming hormone therapy (GAHT) and gender-affirming surgery (GAS) may be desired by transgender and gender-diverse (TGD) individuals who want to affirm their gender identity. Testosterone is the basis of GAHT for transgender individuals assigned female at birth (AFAB), whereas GAS can invol...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in endocrinology (Lausanne) 2024-09, Vol.15, p.1416121
Main Authors: Sanna, Elena, Lami, Alessandra, Giacomelli, Giulia, Alvisi, Stefania, Paccapelo, Alexandro, Seracchioli, Renato, Meriggiola, Maria Cristina
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c350t-7d389489d161b3fcd41365abf813974c1a171440cc198b872678a078064760523
container_end_page
container_issue
container_start_page 1416121
container_title Frontiers in endocrinology (Lausanne)
container_volume 15
creator Sanna, Elena
Lami, Alessandra
Giacomelli, Giulia
Alvisi, Stefania
Paccapelo, Alexandro
Seracchioli, Renato
Meriggiola, Maria Cristina
description Gender-affirming hormone therapy (GAHT) and gender-affirming surgery (GAS) may be desired by transgender and gender-diverse (TGD) individuals who want to affirm their gender identity. Testosterone is the basis of GAHT for transgender individuals assigned female at birth (AFAB), whereas GAS can involve hysterectomy, bilateral salpingectomy, bilateral oophorectomy (BO), thorax masculinization, and phalloplasty. Our study aimed to evaluate the effects of GAHT on the bone health of TGD AFAB individuals who have undergone or not undergone BO. This was a single-center, longitudinal study with retrospectively collected data. TGD AFAB GAHT-naïve individuals were enrolled and underwent dual-energy X-ray absorptiometry scans and laboratory tests (hormonal and bone metabolism parameters) at baseline and after 5 and 10 years of GAHT. Two hundred and forty-three TGD AFAB people were included in this study. Seventy-five subjects had completed data for 5 years and 19 subjects for 10 years of GAHT. At baseline, low bone density (Z-score < -2.0) was found in 2.5% (6/243) of subjects for lumbar spine (LS), whereas total hip (TH) and femoral neck (FN) Z-scores and laboratory tests were within the normal female range. After stratifying by physical activity, the physically active group showed significantly higher LS BMD and Z-scores (p ≤ 0.05). Five years after the start of GAHT, a significant reduction in LS (p ≤ 0.05), TH (p ≤ 0.001), and FN (p ≤ 0.01) Z-scores was detected. A significant reduction in the Z-scores of all three bone sites was observed only in the subgroup that had undergone BO. After 5 years of GAHT, estradiol levels were significantly decreased compared to those in baseline (p ≤ 0.001). Significantly higher estradiol levels were detected in the 5-year no-BO subgroup compared to those in the 5-year BO subgroup (p ≤ 0.001). A significant reduction in LS and TH Z-scores were observed after 10 years of GAHT. At this time, estradiol levels were significantly decreased compared to those in baseline (p ≤ 0.01). Bone density in TGD AFAB individuals is comparable to that in their peers prior to GAHT and BO, but those subjects who underwent BO had a reduced Z-score at LS, FN, and TH after 5 years and at LS after 10 years of GAHT.
doi_str_mv 10.3389/fendo.2024.1416121
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_e8330eb4ed8449f5923126e507b3221e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_e8330eb4ed8449f5923126e507b3221e</doaj_id><sourcerecordid>3115502590</sourcerecordid><originalsourceid>FETCH-LOGICAL-c350t-7d389489d161b3fcd41365abf813974c1a171440cc198b872678a078064760523</originalsourceid><addsrcrecordid>eNpVks1u3CAUha2qVROleYEuKpbdeMIFbEM3VRv1J1Kkbto1wnCxHdkwBU-jefsymUmUsAHBOd_lwqmq90A3nEt15TG4uGGUiQ0IaIHBq-oc2lbUjCv2-tn6rLrM-Y6WISgoJd9WZ1xxBVLS8-r-awxIRjTzOpIpkDWZkIfCxkRMztMQ0BGPi5mRmJX0Uyq6LcbtjJ8Ieo92zSR6crTUxvspLVMYyBjTckCvIyaz3RMTHBliMK444rJ_V73xZs54eZovqj_fv_2-_lnf_vpxc_3ltra8oWvdudKrkMqVDnvurRPA28b0XgJXnbBgoAMhqLWgZC871nbS0E7SVnQtbRi_qG6OXBfNnd6maTFpr6OZ9MNGTIM2aZ3sjBol5xR7gU4KoXyjGAfWYkO7njMGWFifj6ztrl_QWQzlteYX0JcnYRr1EP9pANEKKZpC-HgipPh3h3nVy5QtzrMJGHdZc4CmoaxRtEjZUWpTzDmhf6oDVB8SoB8SoA8J0KcEFNOH5zd8sjz-N_8Poz6tbg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3115502590</pqid></control><display><type>article</type><title>Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy</title><source>PubMed Central</source><creator>Sanna, Elena ; Lami, Alessandra ; Giacomelli, Giulia ; Alvisi, Stefania ; Paccapelo, Alexandro ; Seracchioli, Renato ; Meriggiola, Maria Cristina</creator><creatorcontrib>Sanna, Elena ; Lami, Alessandra ; Giacomelli, Giulia ; Alvisi, Stefania ; Paccapelo, Alexandro ; Seracchioli, Renato ; Meriggiola, Maria Cristina</creatorcontrib><description>Gender-affirming hormone therapy (GAHT) and gender-affirming surgery (GAS) may be desired by transgender and gender-diverse (TGD) individuals who want to affirm their gender identity. Testosterone is the basis of GAHT for transgender individuals assigned female at birth (AFAB), whereas GAS can involve hysterectomy, bilateral salpingectomy, bilateral oophorectomy (BO), thorax masculinization, and phalloplasty. Our study aimed to evaluate the effects of GAHT on the bone health of TGD AFAB individuals who have undergone or not undergone BO. This was a single-center, longitudinal study with retrospectively collected data. TGD AFAB GAHT-naïve individuals were enrolled and underwent dual-energy X-ray absorptiometry scans and laboratory tests (hormonal and bone metabolism parameters) at baseline and after 5 and 10 years of GAHT. Two hundred and forty-three TGD AFAB people were included in this study. Seventy-five subjects had completed data for 5 years and 19 subjects for 10 years of GAHT. At baseline, low bone density (Z-score &lt; -2.0) was found in 2.5% (6/243) of subjects for lumbar spine (LS), whereas total hip (TH) and femoral neck (FN) Z-scores and laboratory tests were within the normal female range. After stratifying by physical activity, the physically active group showed significantly higher LS BMD and Z-scores (p ≤ 0.05). Five years after the start of GAHT, a significant reduction in LS (p ≤ 0.05), TH (p ≤ 0.001), and FN (p ≤ 0.01) Z-scores was detected. A significant reduction in the Z-scores of all three bone sites was observed only in the subgroup that had undergone BO. After 5 years of GAHT, estradiol levels were significantly decreased compared to those in baseline (p ≤ 0.001). Significantly higher estradiol levels were detected in the 5-year no-BO subgroup compared to those in the 5-year BO subgroup (p ≤ 0.001). A significant reduction in LS and TH Z-scores were observed after 10 years of GAHT. At this time, estradiol levels were significantly decreased compared to those in baseline (p ≤ 0.01). Bone density in TGD AFAB individuals is comparable to that in their peers prior to GAHT and BO, but those subjects who underwent BO had a reduced Z-score at LS, FN, and TH after 5 years and at LS after 10 years of GAHT.</description><identifier>ISSN: 1664-2392</identifier><identifier>EISSN: 1664-2392</identifier><identifier>DOI: 10.3389/fendo.2024.1416121</identifier><identifier>PMID: 39391880</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>Absorptiometry, Photon ; Adult ; assigned female at birth (AFAB) ; Bone Density - drug effects ; bone health ; Dual-energy X-ray absorptiometry (DXA) ; Endocrinology ; Female ; gender affirming hormonal therapy (GAHT) ; Hormone Replacement Therapy ; Humans ; Longitudinal Studies ; Male ; Middle Aged ; Retrospective Studies ; Sex Reassignment Procedures - methods ; Sex Reassignment Surgery ; testosterone ; Testosterone - blood ; Transgender Persons ; Transsexualism - blood ; Young Adult</subject><ispartof>Frontiers in endocrinology (Lausanne), 2024-09, Vol.15, p.1416121</ispartof><rights>Copyright © 2024 Sanna, Lami, Giacomelli, Alvisi, Paccapelo, Seracchioli and Meriggiola.</rights><rights>Copyright © 2024 Sanna, Lami, Giacomelli, Alvisi, Paccapelo, Seracchioli and Meriggiola 2024 Sanna, Lami, Giacomelli, Alvisi, Paccapelo, Seracchioli and Meriggiola</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c350t-7d389489d161b3fcd41365abf813974c1a171440cc198b872678a078064760523</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464845/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464845/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39391880$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sanna, Elena</creatorcontrib><creatorcontrib>Lami, Alessandra</creatorcontrib><creatorcontrib>Giacomelli, Giulia</creatorcontrib><creatorcontrib>Alvisi, Stefania</creatorcontrib><creatorcontrib>Paccapelo, Alexandro</creatorcontrib><creatorcontrib>Seracchioli, Renato</creatorcontrib><creatorcontrib>Meriggiola, Maria Cristina</creatorcontrib><title>Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy</title><title>Frontiers in endocrinology (Lausanne)</title><addtitle>Front Endocrinol (Lausanne)</addtitle><description>Gender-affirming hormone therapy (GAHT) and gender-affirming surgery (GAS) may be desired by transgender and gender-diverse (TGD) individuals who want to affirm their gender identity. Testosterone is the basis of GAHT for transgender individuals assigned female at birth (AFAB), whereas GAS can involve hysterectomy, bilateral salpingectomy, bilateral oophorectomy (BO), thorax masculinization, and phalloplasty. Our study aimed to evaluate the effects of GAHT on the bone health of TGD AFAB individuals who have undergone or not undergone BO. This was a single-center, longitudinal study with retrospectively collected data. TGD AFAB GAHT-naïve individuals were enrolled and underwent dual-energy X-ray absorptiometry scans and laboratory tests (hormonal and bone metabolism parameters) at baseline and after 5 and 10 years of GAHT. Two hundred and forty-three TGD AFAB people were included in this study. Seventy-five subjects had completed data for 5 years and 19 subjects for 10 years of GAHT. At baseline, low bone density (Z-score &lt; -2.0) was found in 2.5% (6/243) of subjects for lumbar spine (LS), whereas total hip (TH) and femoral neck (FN) Z-scores and laboratory tests were within the normal female range. After stratifying by physical activity, the physically active group showed significantly higher LS BMD and Z-scores (p ≤ 0.05). Five years after the start of GAHT, a significant reduction in LS (p ≤ 0.05), TH (p ≤ 0.001), and FN (p ≤ 0.01) Z-scores was detected. A significant reduction in the Z-scores of all three bone sites was observed only in the subgroup that had undergone BO. After 5 years of GAHT, estradiol levels were significantly decreased compared to those in baseline (p ≤ 0.001). Significantly higher estradiol levels were detected in the 5-year no-BO subgroup compared to those in the 5-year BO subgroup (p ≤ 0.001). A significant reduction in LS and TH Z-scores were observed after 10 years of GAHT. At this time, estradiol levels were significantly decreased compared to those in baseline (p ≤ 0.01). Bone density in TGD AFAB individuals is comparable to that in their peers prior to GAHT and BO, but those subjects who underwent BO had a reduced Z-score at LS, FN, and TH after 5 years and at LS after 10 years of GAHT.</description><subject>Absorptiometry, Photon</subject><subject>Adult</subject><subject>assigned female at birth (AFAB)</subject><subject>Bone Density - drug effects</subject><subject>bone health</subject><subject>Dual-energy X-ray absorptiometry (DXA)</subject><subject>Endocrinology</subject><subject>Female</subject><subject>gender affirming hormonal therapy (GAHT)</subject><subject>Hormone Replacement Therapy</subject><subject>Humans</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Sex Reassignment Procedures - methods</subject><subject>Sex Reassignment Surgery</subject><subject>testosterone</subject><subject>Testosterone - blood</subject><subject>Transgender Persons</subject><subject>Transsexualism - blood</subject><subject>Young Adult</subject><issn>1664-2392</issn><issn>1664-2392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVks1u3CAUha2qVROleYEuKpbdeMIFbEM3VRv1J1Kkbto1wnCxHdkwBU-jefsymUmUsAHBOd_lwqmq90A3nEt15TG4uGGUiQ0IaIHBq-oc2lbUjCv2-tn6rLrM-Y6WISgoJd9WZ1xxBVLS8-r-awxIRjTzOpIpkDWZkIfCxkRMztMQ0BGPi5mRmJX0Uyq6LcbtjJ8Ieo92zSR6crTUxvspLVMYyBjTckCvIyaz3RMTHBliMK444rJ_V73xZs54eZovqj_fv_2-_lnf_vpxc_3ltra8oWvdudKrkMqVDnvurRPA28b0XgJXnbBgoAMhqLWgZC871nbS0E7SVnQtbRi_qG6OXBfNnd6maTFpr6OZ9MNGTIM2aZ3sjBol5xR7gU4KoXyjGAfWYkO7njMGWFifj6ztrl_QWQzlteYX0JcnYRr1EP9pANEKKZpC-HgipPh3h3nVy5QtzrMJGHdZc4CmoaxRtEjZUWpTzDmhf6oDVB8SoB8SoA8J0KcEFNOH5zd8sjz-N_8Poz6tbg</recordid><startdate>20240926</startdate><enddate>20240926</enddate><creator>Sanna, Elena</creator><creator>Lami, Alessandra</creator><creator>Giacomelli, Giulia</creator><creator>Alvisi, Stefania</creator><creator>Paccapelo, Alexandro</creator><creator>Seracchioli, Renato</creator><creator>Meriggiola, Maria Cristina</creator><general>Frontiers Media S.A</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20240926</creationdate><title>Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy</title><author>Sanna, Elena ; Lami, Alessandra ; Giacomelli, Giulia ; Alvisi, Stefania ; Paccapelo, Alexandro ; Seracchioli, Renato ; Meriggiola, Maria Cristina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c350t-7d389489d161b3fcd41365abf813974c1a171440cc198b872678a078064760523</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Absorptiometry, Photon</topic><topic>Adult</topic><topic>assigned female at birth (AFAB)</topic><topic>Bone Density - drug effects</topic><topic>bone health</topic><topic>Dual-energy X-ray absorptiometry (DXA)</topic><topic>Endocrinology</topic><topic>Female</topic><topic>gender affirming hormonal therapy (GAHT)</topic><topic>Hormone Replacement Therapy</topic><topic>Humans</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Sex Reassignment Procedures - methods</topic><topic>Sex Reassignment Surgery</topic><topic>testosterone</topic><topic>Testosterone - blood</topic><topic>Transgender Persons</topic><topic>Transsexualism - blood</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sanna, Elena</creatorcontrib><creatorcontrib>Lami, Alessandra</creatorcontrib><creatorcontrib>Giacomelli, Giulia</creatorcontrib><creatorcontrib>Alvisi, Stefania</creatorcontrib><creatorcontrib>Paccapelo, Alexandro</creatorcontrib><creatorcontrib>Seracchioli, Renato</creatorcontrib><creatorcontrib>Meriggiola, Maria Cristina</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in endocrinology (Lausanne)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sanna, Elena</au><au>Lami, Alessandra</au><au>Giacomelli, Giulia</au><au>Alvisi, Stefania</au><au>Paccapelo, Alexandro</au><au>Seracchioli, Renato</au><au>Meriggiola, Maria Cristina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy</atitle><jtitle>Frontiers in endocrinology (Lausanne)</jtitle><addtitle>Front Endocrinol (Lausanne)</addtitle><date>2024-09-26</date><risdate>2024</risdate><volume>15</volume><spage>1416121</spage><pages>1416121-</pages><issn>1664-2392</issn><eissn>1664-2392</eissn><abstract>Gender-affirming hormone therapy (GAHT) and gender-affirming surgery (GAS) may be desired by transgender and gender-diverse (TGD) individuals who want to affirm their gender identity. Testosterone is the basis of GAHT for transgender individuals assigned female at birth (AFAB), whereas GAS can involve hysterectomy, bilateral salpingectomy, bilateral oophorectomy (BO), thorax masculinization, and phalloplasty. Our study aimed to evaluate the effects of GAHT on the bone health of TGD AFAB individuals who have undergone or not undergone BO. This was a single-center, longitudinal study with retrospectively collected data. TGD AFAB GAHT-naïve individuals were enrolled and underwent dual-energy X-ray absorptiometry scans and laboratory tests (hormonal and bone metabolism parameters) at baseline and after 5 and 10 years of GAHT. Two hundred and forty-three TGD AFAB people were included in this study. Seventy-five subjects had completed data for 5 years and 19 subjects for 10 years of GAHT. At baseline, low bone density (Z-score &lt; -2.0) was found in 2.5% (6/243) of subjects for lumbar spine (LS), whereas total hip (TH) and femoral neck (FN) Z-scores and laboratory tests were within the normal female range. After stratifying by physical activity, the physically active group showed significantly higher LS BMD and Z-scores (p ≤ 0.05). Five years after the start of GAHT, a significant reduction in LS (p ≤ 0.05), TH (p ≤ 0.001), and FN (p ≤ 0.01) Z-scores was detected. A significant reduction in the Z-scores of all three bone sites was observed only in the subgroup that had undergone BO. After 5 years of GAHT, estradiol levels were significantly decreased compared to those in baseline (p ≤ 0.001). Significantly higher estradiol levels were detected in the 5-year no-BO subgroup compared to those in the 5-year BO subgroup (p ≤ 0.001). A significant reduction in LS and TH Z-scores were observed after 10 years of GAHT. At this time, estradiol levels were significantly decreased compared to those in baseline (p ≤ 0.01). Bone density in TGD AFAB individuals is comparable to that in their peers prior to GAHT and BO, but those subjects who underwent BO had a reduced Z-score at LS, FN, and TH after 5 years and at LS after 10 years of GAHT.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>39391880</pmid><doi>10.3389/fendo.2024.1416121</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1664-2392
ispartof Frontiers in endocrinology (Lausanne), 2024-09, Vol.15, p.1416121
issn 1664-2392
1664-2392
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_e8330eb4ed8449f5923126e507b3221e
source PubMed Central
subjects Absorptiometry, Photon
Adult
assigned female at birth (AFAB)
Bone Density - drug effects
bone health
Dual-energy X-ray absorptiometry (DXA)
Endocrinology
Female
gender affirming hormonal therapy (GAHT)
Hormone Replacement Therapy
Humans
Longitudinal Studies
Male
Middle Aged
Retrospective Studies
Sex Reassignment Procedures - methods
Sex Reassignment Surgery
testosterone
Testosterone - blood
Transgender Persons
Transsexualism - blood
Young Adult
title Bone health in transgender assigned female at birth people: effects of gender-affirming hormone therapy and gonadectomy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T14%3A02%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bone%20health%20in%20transgender%20assigned%20female%20at%20birth%20people:%20effects%20of%20gender-affirming%20hormone%20therapy%20and%20gonadectomy&rft.jtitle=Frontiers%20in%20endocrinology%20(Lausanne)&rft.au=Sanna,%20Elena&rft.date=2024-09-26&rft.volume=15&rft.spage=1416121&rft.pages=1416121-&rft.issn=1664-2392&rft.eissn=1664-2392&rft_id=info:doi/10.3389/fendo.2024.1416121&rft_dat=%3Cproquest_doaj_%3E3115502590%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c350t-7d389489d161b3fcd41365abf813974c1a171440cc198b872678a078064760523%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3115502590&rft_id=info:pmid/39391880&rfr_iscdi=true